BioSpace News Archive

ZOLL® Medical Corporation announced that it has successfully completed its previously announced acquisition of Itamar™ Medical Ltd., a medical device and digital health company that provides at-home testing for sleep apnea.

Kodiak Sciences Inc. announced that it has completed enrollment in its BEACON Phase 3 clinical trial of KSI-301, Kodiak’s anti-VEGF antibody biopolymer conjugate, in patients with macular edema due to retinal vein occlusion.

Inogen, Inc., a medical technology company offering innovative respiratory products for use in the homecare setting, announced that the Company’s presentation at the 40th Annual J.P. Morgan Healthcare Conference has been moved due to the conference moving into a virtual format.

Bionomics Limited, a clinical-stage biopharmaceutical company, announced the pricing of its initial public offering in the United States of 1,622,000 American Depositary Shares, each representing 180 ordinary shares of Bionomics, at an initial public offering price of US$12.35 per ADS.

Notable Labs, Inc., a clinical-stage platform therapeutics company, announced results from two ongoing Phase 2 clinical trials examining the performance of its high-fidelity predictive precision medicines platform in predicting clinical outcomes in acute myelogenous leukemia standard-of-care settings.

Verge Genomics announced today it has closed an oversubscribed $98 million equity financing.

NeuroPace, Inc. today announced that Mike Favet, CEO, Rebecca Kuhn, CFO and VP of Finance and Administration, and Irina Ridley, General Counsel and Corporate Secretary will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th, 2022, at 8:15 am Pacific Time / 11:15am Eastern Time.

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed in Phase 2/3 Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for people with USH2A mediated retinitis pigmentosa (RP) and Usher syndrome.

Applied Therapeutics, Inc. today announced the initiation of a registrational phase 2/3 study of AT-007 in Sorbitol Dehydrogenase (SORD) Deficiency.

Kymera Therapeutics, Inc. today announced significant advances across its clinical stage pipeline, new programs and platform investments at its first R&D Day.